# EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

> **NCT02705313** · — · APPROVED_FOR_MARKETING · sponsor: **Advanced Accelerator Applications**

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 177Lu-DOTA0-Tyr3-Octreotate

## Key facts

- **NCT ID:** NCT02705313
- **Lead sponsor:** Advanced Accelerator Applications
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02705313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02705313, "EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02705313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*